The potential mechanism for metformin’s anti-cancer properties may include the inhibition of mTOR signaling by activating the adenosine monophosphate (AMP)-activated protein kinase (AMPK)-dependent pathway which disturbs protein synthesis and suppresses cell growth and proliferation by reducing insulin levels and glucose uptake [195,196,197]. The gene discussed is INS; the disease is cancer.